Application of hesperidin to preparation of medicine for treating diabetic gangrene

A technology of diabetic gangrene and hesperidin, which is applied in the field of application of hesperidin in the preparation of drugs for treating diabetic gangrene, can solve the problems of large side effects and low compliance, and achieve the effects of low side effects, improvement of symptoms and improvement of compliance

Inactive Publication Date: 2018-05-18
珠海霍普金斯医药研究院股份有限公司 +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The purpose of the present invention is to provide the application of hesperidin in the preparation of drugs for the treatment of diabetic gangrene, so as to solve the problems of large side effects and low compliance in the drug treatment of diabetic gangrene in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of hesperidin to preparation of medicine for treating diabetic gangrene
  • Application of hesperidin to preparation of medicine for treating diabetic gangrene

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Hesperidin inhibits the secretion of inflammatory factors in macrophages in vitro

[0018] The mouse peritoneal macrophage cell line Raw 264.7 was cultured in a cell culture incubator with DMEM medium containing 10% fetal bovine serum. After the cells grow well, digest the cells, and dilute 100 μL of the cell suspension according to 1×10 6 / L concentration was inoculated into 96-well plates, and then divided into blank control group, model group, and dexamethasone group (dexamethasone 10 -7 mol / L) and hesperidin high concentration group (10 -5 mol / L), medium concentration group (10 -6 mol / L), low concentration group (10 -7 mol / L), and 5 wells were made for each concentration group. Except for the blank group which was added with 100 μL of PBS, the rest of the groups were stimulated with 5 mg / L lipopolysaccharide LPS. After incubation for 48 hours, the cell supernatant was collected and centrifuged to detect the contents of TNF-α and IL-6 in the supernatant accordin...

Embodiment 2

[0024] Hesperidin promotes wound healing in rats with diabetic gangrene

[0025] After adaptive feeding of SD rats, a one-time intraperitoneal injection of streptozotocin (STZ) 40 mg / kg was used to prepare a diabetic model. Two weeks after the blood sugar of the rats increased, a stamp was used to make a rectangular mark on the back of the left foot of the rat, and the full-thickness skin (2mm×5mm) marked by the rectangle was cut off, and the rats in the model group were wounded in the same way. The wound healing was observed every day, and complete epithelial coverage was used as the basis for wound healing. The experiment was divided into 5 groups, metformin high-dose group (200mg / kg), metformin low-dose group (50mg / kg), hesperidin high-dose group (200mg / kg), hesperidin low-dose group (50mg / kg) and model groups. The drug was given by intragastric administration once a day, and the model group was given the same volume of drinking water by intragastric administration.

[0...

Embodiment 3

[0031] Zhang Moumou, female, 60 years old, the skin of the instep of the left foot had turned black when she went to see a doctor, and the skin tissue had certain redness and swelling and ulceration and necrosis of the instep. Hesperidin 2g was taken twice, 4 weeks as a course of treatment. After taking the medicine for one month, the symptoms improved significantly. The feet were festered and necrotic, dry and black, and suppurative infection was significantly improved. Compared with before the treatment, no abnormalities of the liver, kidney, heart and brain were found. Continue to take medicine again and fully recover after three months.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to novel application of hesperidin and in particular relates to application of the hesperidin to preparation of a medicine for treating diabetic gangrene. The application of thehesperidin to treatment of the diabetic gangrene, provided by the invention, provides another choice for treating the disease; the hesperidin is extracted from plants and has low side effect, so thatthe compliance of treatment can be improved; the hesperidin provided by the invention can be used for improving symptoms of the diabetic gangrene and can be used for greatly reducing fester and necrosis, dryness and blackening, suppuration and infection of four limbs and feet and the like.

Description

technical field [0001] The invention relates to a new application of hesperidin, in particular to the application of hesperidin in the preparation of medicines for treating diabetic gangrene. Background technique [0002] Diabetic gangrene mostly occurs in middle-aged and elderly people; more men than women, the ratio of men to women is 3:2; the average course of diabetes is about 10 years, gangrene is more common in the lower limbs, accounting for 92.5%, rare in the upper limbs, accounting for 7.5%; unilateral disease It accounts for about 80%, and bilateral simultaneous disease accounts for about 20%; simultaneous gangrene of toes and soles is more common, accounting for 77.5%; simultaneous gangrene of toes and lower legs accounts for 5%, and only calf gangrene accounts for 5%; toe or finger gangrene Incidence accounted for 12.5%. Diabetic gangrene is more common in obese or adult diabetic patients with a long course of disease, with an average of about 10 years. The low...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61P3/10A61P25/00A61P17/00
CPCA61K31/7048
Inventor 曹文强王重庆赵柏松
Owner 珠海霍普金斯医药研究院股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap